ShareValue scores for 1312.HK: Valuation 67, Quality 23, Growth 58, Health 37.

1312.HK
HKEX

Tongfang Kontafarma Holdings Ltd

HK$0.03(0.00%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

3% to 19%
Valuation
67
Fair Value
Price vs Value
Quality
23
Weak
Business Strength
Growth
58
Moderate
Revenue & Earnings
Health
37
Stressed
Financial Stability
Momentum
53
Neutral
Price Trend

Company Details

About

Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediates in Mainland China, Singapore, Taiwan, and internationally. The company operates through Pharmaceutical Business and Fitness Business segments. It provides prescription drugs, including chemical drugs and prescribed traditional Chinese medicines; operates fitness and yoga centers, as well as franchise business; and provides management and consultation services for fitness and health activities. The company also provides corporate advisory services; and researches and develops medical products. The company was formerly known as Tongfang Kontafarma Holdings Limited and changed its name to Kontafarma China Holdings Limited in September 2022. Kontafarma China Holdings Limited was incorporated in 2011 and is headquartered in Wan Chai, Hong Kong. Kontafarma China Holdings Limited is a subsidiary of Waranty Assets Management (Hk) Limited.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026